Work

Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz394.066

Authors: A.M. Arance, H. Gogas, B. Dreno, K.T. Flaherty, L. Demidov, D. Stroyakovskiy, Z. Eroglu, P.F. Ferrucci, J. Pigozzo, P. Rutkowski, J. Mackiewicz, I. Rooney, A. Voulgari, S. Troutman, B. Pitcher, Y. Yan, J.M.G. Larkin

Institutions: Hospital Clínic de Barcelona, National and Kapodistrian University of Athens, Centre Hospitalier Universitaire de Nantes, Nantes Université, Harvard University, Massachusetts General Hospital, Russian Cancer Research Center NN Blokhin, Moscow City Oncology Hospital №62, Moffitt Cancer Center, European Institute of Oncology, Istituto Oncologico Veneto, The Maria Sklodowska-Curie National Research Institute of Oncology, Poznan University of Medical Sciences, Genentech, Roche (United Kingdom), F. Hoffmann-La Roche AG, Roche (Canada), Royal Marsden NHS Foundation Trust, Royal Marsden Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2978433459

FWCI: 2.084

Cites:

Cited by: 29

Related to: 10